Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Contactless photoconductance study on undoped and doped nanocrystalline diamond films.
Seshan V, Murthy DH, Castellanos-Gomez A, Sachdeva S, Ahmad HA, Janssens SD, Janssen W, Haenen K, van der Zant HS, Sudhölter EJ, Savenije TJ, de Smet LC. Seshan V, et al. ACS Appl Mater Interfaces. 2014 Jul 23;6(14):11368-75. doi: 10.1021/am501907q. Epub 2014 Jul 14. ACS Appl Mater Interfaces. 2014. PMID: 24918631
Pick-up and drop transfer of diamond nanosheets.
Seshan V, Island JO, van Leeuwen R, Venstra WJ, Schneider BH, Janssens SD, Haenen K, Sudhölter EJ, de Smet LC, van der Zant HS, Steele GA, Castellanos-Gomez A. Seshan V, et al. Nanotechnology. 2015 Mar 27;26(12):125706. doi: 10.1088/0957-4484/26/12/125706. Epub 2015 Mar 5. Nanotechnology. 2015. PMID: 25742057
Experiences of Students with Disabilities Enrolling in Higher Education: A Qualitative Study in the United Arab Emirates.
Arsyad Subu M, Mottershead R, Mahmoud Sallam A, Maria Dias J, Kavumpurath J, Refaat Ahmed F, Hesham Hijazi H, Sara Abraham M, Mohamed Al Marzouqi A, Seshan V, Mohammed Elabed S, Rajeh Saifan A, Azizur Rahman S, Al Yateem N. Arsyad Subu M, et al. Among authors: seshan v. F1000Res. 2025 Jan 2;14:14. doi: 10.12688/f1000research.158481.1. eCollection 2025. F1000Res. 2025. PMID: 39830092 Free PMC article.
Improving Accuracy of Somatic Mutation Profiling in Large Epidemiologic Studies: Addressing Cases without Matched Normal Samples.
Arora A, Luo L, Kostrzewa CE, Reiner A, Seshan V, Ernstoff MS, Edmiston SN, Conway K, Gorlov I, Busam K, Orlow I, Hernando E, Thomas NE, Berwick M, Begg CB, Shen R; InterMEL. Arora A, et al. Among authors: seshan v. bioRxiv [Preprint]. 2024 Oct 31:2024.10.28.617052. doi: 10.1101/2024.10.28.617052. bioRxiv. 2024. PMID: 39554118 Free PMC article. Preprint.
Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma.
Kim K, Alam SM, Kuo F, Chen Z, Yip W, Katims AB, Chu C, Lenis AT, Hu W, Gokturk Ozcan G, Chen JF, Firouzi S, Elhanati Y, Clinton TN, Aulitzky A, Almassi N, Fujii Y, Tracey AT, Reisz PA, Budhu S, Vuong L, Eichholz J, Woo HJ, Nogueira L, Gao SP, Scherz A, Aggen DH, Rosenberg JE, Pietzak EJ, Seshan V, Greenbaum B, Becker A, Akin O, Iyer G, Al-Ahmadie H, Hakimi AA, Merghoub T, Solit DB, Coleman JA. Kim K, et al. Among authors: seshan v. Eur Urol. 2024 Nov 15:S0302-2838(24)02686-1. doi: 10.1016/j.eururo.2024.10.024. Online ahead of print. Eur Urol. 2024. PMID: 39550333 Free article.
DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance.
Conway K, Edmiston SN, Vondras A, Reiner A, Corcoran DL, Shen R, Parrish EA, Hao H, Lin L, Kenney JM, Ilelaboye G, Kostrzewa CE, Kuan PF, Busam KJ, Lezcano C, Lee TK, Hernando E, Googe PB, Ollila DW, Moschos S, Gorlov I, Amos CI, Ernstoff MS, Cust AE, Wilmott JS, Scolyer RA, Mann GJ, Vergara IA, Ko J, Rees JR, Yan S, Nagore E, Bosenberg M, Rothberg BG, Osman I, Lee JE, Saenger Y, Bogner P, Thompson CL, Gerstenblith M, Holmen SL, Funchain P, Brunsgaard E, Depcik-Smith ND, Luo L, Boyce T, Orlow I, Begg CB, Berwick M, Thomas NE; InterMEL Study Group. Conway K, et al. JCO Precis Oncol. 2024 Nov;8:e2400375. doi: 10.1200/PO-24-00375. Epub 2024 Nov 7. JCO Precis Oncol. 2024. PMID: 39509669
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation.
Kumar A, Soumerai J, Abramson JS, Barnes JA, Caron P, Chhabra S, Chabowska M, Dogan A, Falchi L, Grieve C, Haydu JE, Johnson PC, Joseph A, Kelly HE, Labarre A, Lue JK, Martignetti R, Mi J, Moskowitz A, Owens C, Plummer S, Puccio M, Salles G, Seshan V, Simkins E, Slupe N, Zhang H, Zelenetz AD. Kumar A, et al. Among authors: seshan v. Blood. 2025 Jan 30;145(5):497-507. doi: 10.1182/blood.2024025563. Blood. 2025. PMID: 39437708 Free article. Clinical Trial.
182 results